uniQure (NASDAQ:QURE) Shares Gap Up – Should You Buy?

Shares of uniQure (NASDAQ:QURE) gapped up prior to trading on Tuesday . The stock had previously closed at $17.43, but opened at $17.88. uniQure shares last traded at $16.88, with a volume of 148,236 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada raised their price target on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Stifel Nicolaus upped their price target on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald raised their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

uniQure Stock Down 0.7 %

The company has a market capitalization of $843.25 million, a PE ratio of -3.49 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business has a fifty day moving average of $8.36 and a 200 day moving average of $6.86.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities research analysts anticipate that uniQure will post -3.82 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. abrdn plc lifted its stake in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. acquired a new stake in uniQure during the third quarter worth approximately $7,360,000. Point72 Asset Management L.P. lifted its position in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after buying an additional 752,889 shares during the last quarter. FMR LLC boosted its holdings in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares in the last quarter. Finally, Privium Fund Management B.V. grew its position in shares of uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.